Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Fiche publication
Date publication
février 2016
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOLOGNA Serge
Tous les auteurs :
Lepretre S, Touzart A, Vermeulin T, Picquenot JM, Tanguy-Schmidt A, Salles G, Lamy T, Béné MC, Raffoux E, Huguet F, Chevallier P, Bologna S, Bouabdallah R, Benichou J, Brière J, Moreau A, Tallon-Simon V, Seris S, Graux C, Asnafi V, Ifrah N, Macintyre E, Dombret H
Lien Pubmed
Résumé
This study evaluated the efficacy of pediatric-like acute lymphoblastic leukemia (ALL) therapy in adults with lymphoblastic lymphoma (LL).
Mots clés
Adolescent, Adult, Antineoplastic Combined Chemotherapy Protocols, therapeutic use, Cell Cycle Proteins, genetics, Central Nervous System Diseases, etiology, Consolidation Chemotherapy, methods, Disease-Free Survival, F-Box Proteins, genetics, Female, Hematopoietic Stem Cell Transplantation, Humans, Induction Chemotherapy, methods, L-Lactate Dehydrogenase, blood, Maintenance Chemotherapy, methods, Male, Middle Aged, PTEN Phosphohydrolase, genetics, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, Precursor Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, drug therapy, Prospective Studies, Receptor, Notch1, genetics, Recurrence, Survival Rate, Treatment Outcome, Ubiquitin-Protein Ligases, genetics, Young Adult, ras Proteins, genetics
Référence
J. Clin. Oncol.. 2016 Feb;34(6):572-80